Finegold / Bensimon / Daar | BioIndustry Ethics | E-Book | sack.de
E-Book

E-Book, Englisch, 384 Seiten

Finegold / Bensimon / Daar BioIndustry Ethics


E-Book, Englisch, 384 Seiten

ISBN: 978-0-08-049251-3
Verlag: Elsevier Science & Techn.
Format: EPUB
 Kopierschutz: 6 - ePub Watermark

This book is the first systematic, detailed treatment of the approaches to ethical issues taken by biotech and pharmaceutical companies. The application of genetic/genomic technologies raises a whole spectrum of ethical questions affecting global health that must be addressed. Topics covered in this comprehensive survey include considerations for bioprospecting in transgenics, genomics, drug discovery, and nutrigenomics, as well as how to improve stakeholder relations, design ethical clinical trials, avoid conflicts of interest, and establish ethics advisory boards. The expert authors represent multiple disciplines including law, medicine, bioinformatics, pharmaceutics, business, and ethics.
Finegold / Bensimon / Daar BioIndustry Ethics jetzt bestellen!

Autoren/Hrsg.

Finegold, David L.
Bensimon, Cecile M
Daar, Abdallah S.
Eaton, Margaret L.
Godard, Beatrice
Knoppers, Bartha Maria
M, Bartha
Mackie, Jocelyn
Singer, Peter A.

Weitere Infos & Material

1;BIOINDUSTRY ETHICS;3
1.1;BIOINDUSTRY ETHICS;5
1.1.1;Contents;7
1.1.2;Research Team;9
1.1.3;Preface;11
1.1.4;Acknowledgments;13
1.1.5;Introduction;15
1.1.5.1;ETHICAL ISSUES CONFRONTING BIOSCIENCE COMPANIES;16
1.1.5.2;WHY SHOULD BIOSCIENCE FIRMS CARE ABOUT ETHICS?;18
1.1.5.3;ETHICISTS AND THE BIOSCIENCE INDUSTRY;22
1.1.5.4;A NEW APPROACH: BIOSCIENCE BUSINESS ETHICS;26
1.1.5.5;STRUCTURE OF THE BOOK;28
1.1.6;Merck: Staying the Course;33
1.1.6.1;INTRODUCTION;33
1.1.6.2;FOCUSING ON PATIENTS AND THE LONG TERM;35
1.1.6.3;ETHICS RESOURCE CENTERS;43
1.1.6.4;INTERNAL ETHICAL PRACTICES;44
1.1.6.5;ASSESSING THE IMPACT;50
1.1.6.6;BENEFITS OF AN ETHICAL APPROACH;52
1.1.6.7;ETHICAL ISSUES;55
1.1.6.8;DRUG PRICING, ACCESS, AND INTELLECTUAL PROPERTY;59
1.1.6.9;CLINICAL TRIALS AND PUBLICATION OF RESULTS;61
1.1.6.10;WHAT DRUGS TO DEVELOP;64
1.1.6.11;CHALLENGES FOR THE FUTURE;65
1.1.7;Genzyme: Putting Patients First;69
1.1.7.1;INTRODUCTION;69
1.1.7.2;PUTTING THE PATIENT FIRST: GENZYMEÌS APPROACH TO ETHICAL ISSUES;72
1.1.7.3;ETHICAL ISSUES;73
1.1.7.4;ETHICAL MECHANISMS;79
1.1.7.5;SUSTAINING THE GENZYME CULTURE;83
1.1.7.6;CONCLUSION;85
1.1.8;Millennium pharmaceuticals, Inc.: Creating and Sustaining Corporate Values;87
1.1.8.1;INTRODUCTION;87
1.1.8.2;MILLENNIUM PHARMACEUTICALS INC.;88
1.1.8.3;INSTITUTIONALIZING CORE VALUES AND ETHICS;94
1.1.8.4;ETHICS EDUCATION PROGRAMS;101
1.1.8.5;IMPACT OF INSTITUTIONALIZATION OF VALUES AND ETHICS;109
1.1.8.6;PRESERVING A FOCUS ON CORE VALUES;118
1.1.8.7;THE FUTURE;119
1.1.9;Maxim Pharmaceuticals (A): Internal and External Dialogues;125
1.1.9.1;AN UNUSUAL BIOTECH LEADER;125
1.1.9.2;THE IMPACT OF BUSINESS ETHICS IN THE BIOSCIENCE INDUSTRY;126
1.1.9.3;COMPANY HISTORY;128
1.1.9.4;EMBEDDING CORE VALUES;129
1.1.9.5;MECHANISMS FOR EMBEDDING CORE VALUES;130
1.1.9.6;BUILDING A SUCCESSFUL GLOBAL BOARD;131
1.1.9.7;ANNUAL STRATEGIC RETREAT;133
1.1.9.8;DEALING WITH ETHICAL ISSUES;136
1.1.9.9;MAXIM PHARMACEUTICALS (B);139
1.1.10;Diversa Inc.: Ethical Issues in Bioprospecting Partnerships;141
1.1.10.1;FROM BIOPIRACY TO BIOPROSPECTING;141
1.1.10.2;THE COMPANY;143
1.1.10.3;THE CONTEXT FOR BIOPROSPECTING PARTNERSHIPS;147
1.1.10.4;DIVERSAÌS BIODIVERSITY COLLABORATIONS;147
1.1.10.5;PROCESS FOR ESTABLISHING AND IMPLEMENTING COLLABORATIVE AGREEMENTS;149
1.1.10.6;ETHICAL DECISION MAKING;151
1.1.10.7;TOWARD THE FUTURE;154
1.1.10.8;DIVERSA INC. (B);156
1.1.10.9;DIVERSA INC. (C);161
1.1.10.10;DIVERSA INC. (D);164
1.1.11;Pipeline Biotech A/S: Competing Regulatory Regimes for Laboratory Animal Experiments;167
1.1.11.1;INTRODUCTION;167
1.1.11.2;COMPANY HISTORY;169
1.1.11.3;BUSINESS MODEL AND ETHICAL APPROACH;171
1.1.11.4;EMPOWERING THE WORKFORCE;173
1.1.11.5;ETHICAL ISSUES AT PIPELINE;177
1.1.11.6;CONCLUSION;180
1.1.12;TGN Biotech: A Start-Up with Ethical Roots;181
1.1.12.1;WHAT NOW?;182
1.1.12.2;TGN BIOTECH;182
1.1.12.3;TGNÌS MARKET;183
1.1.12.4;SEMENESISTM;185
1.1.12.5;WHY PIGS AND WHY SEMEN?;185
1.1.12.6;THE ETHICAL ISSUES;186
1.1.12.7;MECHANISMS FOR A TRANSPARENT PROCESS;189
1.1.12.8;FUTURE POSSIBILITIES;195
1.1.12.9;WHAT NEXT?;196
1.1.13;Interleukin Genetics and Alticor: An Unlikely Partnership;197
1.1.13.1;INTRODUCTION;197
1.1.13.2;COMPANY ORIGINS;200
1.1.13.3;EXPLORING THE ETHICS OF GENETIC TESTING;202
1.1.13.4;FAILED EFFORTS TO BUILD A PERSONALIZED MEDICINE BUSINESS;203
1.1.13.5;PUTTING ETHICS EXPERTS IN CHARGE;204
1.1.13.6;APPROACH TO ETHICAL ISSUES;208
1.1.13.7;PROPOSED ALTICOR DEAL;210
1.1.13.8;INTERLEUKIN GENETICS AND ALTICOR: AN UNUSUAL PARTNERSHIP;211
1.1.13.9;CREATING AN ETHICAL APPROACH TO NUTRIGENOMICS;212
1.1.14;Sciona Ltd.: A Pioneer in Nutrigenomics: The Path to Consumer Acceptance;215
1.1.14.1;INTRODUCTION;215
1.1.14.2;BACKGROUND;216
1.1.14.3;PRODUCT LAUNCH;217
1.1.14.4;ETHICAL CONSIDERATIONS;218
1.1.14.5;THE CASE FOR ETHICS;219
1.1.14.6;APPLICATION TO THE HUMAN GENETICS COMMISSION;223
1.1.14.7;PUBLIC OPPOSITION;223
1.1.14.8;RESULTS;229
1.1.14.9;THE HGC RECOMMENDATIONS;230
1.1.14.10;TOWARD THE FUTURE;232
1.1.15;Affymetrix, Inc.: Using Corporate Ethics Advice;233
1.1.15.1;INTRODUCTION;233
1.1.15.2;DNA CHIP TECHNOLOGY;233
1.1.15.3;APPLICATIONS OF DNA CHIPS;234
1.1.15.4;COMPANY HISTORY;235
1.1.15.5;AFFYMETRIX ETHICS ADVISORY COMMITTEE FORMATION;237
1.1.15.6;OPERATION OF THE ETHICS COMMITTEE;248
1.1.15.7;ADVICE PROVIDED BY THE ETHICS ADVISORY COMMITTEE;255
1.1.15.8;THE FUTURE OF ETHICS AT AFFYMETRIX;261
1.1.15.9;CONCLUSION;263
1.1.16;PharmaSNPs Inc.: Creating an Ethics Advisory Board;265
1.1.16.1;INTRODUCTION;265
1.1.16.2;THE COMPANY;266
1.1.16.3;HOW A PHARMACOGENOMICS STUDY WORKS;267
1.1.16.4;CREATING AND IMPLEMENTING AN EAB;268
1.1.16.5;THE EAB PROCESS;270
1.1.16.6;ROLE OF THE COMPANY;272
1.1.16.7;EAB-COMPANY RELATIONSHIP;272
1.1.16.8;EXAMPLES OF ETHICAL ISSUES;274
1.1.16.9;LESSONS LEARNED;277
1.1.16.10;CONCLUSION;279
1.1.16.11;CASE (B): POSTSCRIPT;279
1.1.17;Monsanto Company: Bio- Agriculture Pioneer;281
1.1.17.1;A LIGHTNING ROD FOR ETHICAL CONTROVERSIES;281
1.1.17.2;THE POLARIZED DEBATE;287
1.1.17.3;MONSANTO UNDER ATTACK;290
1.1.17.4;MONSANTO COMPANY (B);295
1.1.17.5;THE NEW MONSANTO;300
1.1.17.6;THE IMPACT OF THE PLEDGE ON MONSANTO;308
1.1.17.7;THE IMPACT OF THE PLEDGE EXTERNALLY;309
1.1.17.8;A MORE NUANCED PUBLIC DEBATE;310
1.1.17.9;MEASURING THE EFFECTIVENESS OF THE PLEDGE;311
1.1.17.10;TOWARD THE FUTURE;313
1.1.18;Novo Nordisk: The Triple Bottom Line;315
1.1.18.1;INTRODUCTION;315
1.1.18.2;THE COMPANY;316
1.1.18.3;MAKING THE CASE FOR ACTING RESPONSIBLY;319
1.1.18.4;THE TRIPLE BOTTOM LINE;323
1.1.18.5;FUTURE CHALLENGES;342
1.1.19;Conclusion: Lessons for Companies and Future Issues;345
1.1.19.1;WHAT ETHICAL ISSUES DO BIOSCIENCE COMPANIES FACE?;345
1.1.19.2;ISSUE 1: FINANCIAL PRESSURES;346
1.1.19.3;ISSUE 2: DEVELOPING CUTTING-EDGE TECHNOLOGIES;347
1.1.19.4;ISSUE 3: RESEARCH ETHICS;347
1.1.19.5;ISSUE 4: REGULATORY GUIDELINES INSUFFICIENT;348
1.1.19.6;ISSUE 5: MARKETING AND DELIVERY OF PRODUCTS;349
1.1.19.7;ISSUE 6: VALUE, PRICING, AND ACCESS TO PRODUCTS;350
1.1.19.8;ISSUE 7: DOING BUSINESS GLOBALLY;351
1.1.19.9;ISSUE 8: CONFLICTS OF INTEREST;352
1.1.19.10;ISSUE 9: CORPORATE AND SOCIAL RESPONSIBILITY;353
1.1.19.11;ISSUE 10: BUSINESS ETHICS AND GOOD GOVERNANCE;354
1.1.19.12;BUILDING AN ETHICAL DECISION MAKING PROCESS;354
1.1.19.13;KEY FUTURE TRENDS;362
1.1.19.14;CONCLUSION;368
1.1.20;Index;369

Ihre Fragen, Wünsche oder Anmerkungen
Vorname*
Nachname*
Ihre E-Mail-Adresse*
Kundennr.
Ihre Nachricht*
Lediglich mit * gekennzeichnete Felder sind Pflichtfelder.
Wenn Sie die im Kontaktformular eingegebenen Daten durch Klick auf den nachfolgenden Button übersenden, erklären Sie sich damit einverstanden, dass wir Ihr Angaben für die Beantwortung Ihrer Anfrage verwenden. Selbstverständlich werden Ihre Daten vertraulich behandelt und nicht an Dritte weitergegeben. Sie können der Verwendung Ihrer Daten jederzeit widersprechen. Das Datenhandling bei Sack Fachmedien erklären wir Ihnen in unserer Datenschutzerklärung.